Drug Profile
REC 02
Alternative Names: REC-02Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator RECARDIO
- Class Heart failure therapies
- Mechanism of Action Chemokine CXCL12 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for phase-I development in Heart-failure in Austria
- 08 Jan 2016 Phase-I clinical trials in Heart failure in Austria (unspecified route)